Kenvue (KVUE) to Release Quarterly Earnings on Tuesday

Kenvue (NYSE:KVUE) will be releasing its earnings data before the market opens on Tuesday, May 7th. Analysts expect Kenvue to post earnings of $0.26 per share for the quarter. Kenvue has set its FY guidance at $1.10-1.20 EPS and its FY 2024 guidance at 1.100-1.200 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm’s revenue was down 2.7% on a year-over-year basis. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $19.06 on Tuesday. The business’s 50 day simple moving average is $19.84 and its 200 day simple moving average is $20.14. Kenvue has a 1 year low of $17.82 and a 1 year high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 4.20%. The ex-dividend date is Tuesday, May 7th.

Analysts Set New Price Targets

A number of research firms recently commented on KVUE. Sanford C. Bernstein initiated coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target for the company. William Blair started coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating for the company. The Goldman Sachs Group began coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. decreased their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Finally, Royal Bank of Canada reduced their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.